Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA Mosaic HIV Vaccine in Healthy Adults
NCT02218125Phase 1Completed
- Sponsor
- Crucell
- Start
- Sep 2014
- Primary completion
- Nov 2015
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MVA-Mosaic in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Crucell. Primary endpoints: Number of Participants who Experience Adverse Events at 28 days and Number of Participants who Experience Reactogenicity Symptoms at 1 week. Started Sep 2014; status: completed.
02
Drugs
MVA-Mosaic
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02218125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218125.